Summary Radioimmunoscintigraphy (RIS) can be used in the preoperative localisation of ovarian carcinoma to demonstrate uptake of radiolabelled monoclonal antibodies into neoplastic tissue. The tissue uptake of radiotracer was evaluated at laparotomy in 16 patients with suspected ovarian cancer who had preoperative RIS using technetium-99m-labelled monoclonal antibodies SM3 and H17E2. A gamma detection probe ('DP) was used to measure uptake in possible tumour deposits at operation and also the uptake in tissues resected for histology. The percentage uptake of the initial injected dose of radiotracer was also measured in resected tissues. Activity was found to be significantly higher in malignant than in non-neoplastic tissue by all three methods of evaluation. The yDP used peroperatively yielded a 82% sensitivity with a 72% specificity for an uptake ratio of 1.5:1. When tissue was examined immediately after resection, for a 100% specificity the sensitivity was 64%. In vitro measurements of monoclonal antibody uptake by tissue similarly gave a 65% sensitivity with a 100% specificity. Peroperative and immediate post-operative measurements of tissue radioactivity can be performed quickly and conveniently, and in some cases may be of benefit in the localisation of tumour at laparotomy and in providing extra information when tissue is examined by frozen section.
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Ovarian cancer has the worst prognosis of all gynaecological malignancies in the UK. It presents late and is often difficult to differentiate from benign lesions until surgery and histological examination have been performed. The surgical management of ovarian carcinoma is more complex than that of benign tumours and may be dictated by the results of histological frozen sections performed at the time of laparotomy. This is especially important in young women with unilateral ovarian tumours. In addition, a major factor determining the prognosis is whether or not there has been complete resection of the tumour. Therefore, accurate determination of the amount and extent of the tumour is essential. CT scans, pelvic ultrasound and surgical exploration, even when used together, are less than 100% accurate . However, radioimmunoscintigraphy using monoclonal antibodies against polymorphic epithelial mucin and other epitopes may yield more complete preoperative information (Granowska et al., 1984 (Granowska et al., , 1990 (Granowska et al., , 1993 Davies et al., 1985; Epenetos et al., 1985; Jackson et al., 1985; Critchley et al., 1986; Shepherd et al., 1987; Jobling et al., 1990) . We decided to assess the value of peroperative radioimmunodetection (PROD) using a specially designed gamma detection probe (yDP). We have also studied the value of measuring monoclonal antibody uptake in excised tissue as an aid to interpreting a frozen section.
Patients and methods
Sixteen patients having conventional routine radioimmunoscintigraphy prior to surgery for proven or suspected ovarian carcinoma were studied ( monoclonal antibody 24-30 h before surgery. This was followed by conventional radioimmunoscintigraphy at 10 min, 4-6 h and 20-24 h after injection. At laparotomy a gamma detection probe (yDP) was used to evaluate possible sites of tumour. The radioactivity in tissue specimens was measured using an automated gamma counter.
Monoclonal antibodies
The monoclonal antibody SM3 reacts with an epitope on polymorphic epithelial mucin (PEM) (Burchell et al., 1987) ; the monoclonal antibody H17E2 reacts with an epitope of placental and germ cell alkaline phosphatase (Travers & Bodmer, 1984 In the 64 samples probed in vivo, the median uptake ratio for histologically confirmed malignant sites was 4.2:1 compared with 1.0:1 in non-affected sites (U = 820, P <0.001, 95% CI = 1.2-5.2). For specimens probed after resection, the median uptake ratio in malignant tissue was 4.6:1 compared with 2.3:1 in non-neoplastic (U = 27, P = 0.037, 95% CI=0.2-11.1) (Figure 1 ).
In the 58 samples examined for tissue uptake of monoclonal antibody, the median percentage of the initial injected dose per gram of tissue was 7.63 x 10-' % g-1 in malignant tissue compared with 1.97 x 10' % g-' in non-neoplastic tissue (U=528, P<0.0001, 95% CI=4.00X 10-3 to 6.71 x 10-3 % g-') ( Figure 2 ).
The gamma detection probe used during operation had an 82% sensitivity for malignancy with a false-positive rate of 28% when an uptake ratio of 1.5:1 was used (Figure 3 ). An uptake ratio of 2.3:1 yielded a 68% sensitivity for a 19% false-positive rate (Figure 3 ). When used on resected specimens the sensitivity with a zero false-positive rate was 64%.
Measurement of radiotracer uptake by tissue as a percentage of the injected dose per gram had a sensitivity of 81% for malignancy with a 10% false-positive rate. The sensitivity for a zero false-positive rate was 65% (Figure 3 ). 
Discussion
This study demonstrates that a gamma detection probe can be used both per-and post-operatively to detect radiolabelled antibodies bound to ovarian cancer cells. The results also illustrate that detection is most efficient after the tissue is resected either using the yDP or an automated gamma counter. All three methods of detection may potentially be of value in the per-and immediately post-operative detection of False-positive rate (%) ovarian cancer, however a larger study comparing this with other methods of detection would be needed to confirm any clinical worth. Preoperative imaging by radioimmunoscintigraphy has been shown to be of benefit using a variety of radionuclides (Granowska et al., 1984 (Granowska et al., , 1990 Davies et al., 1985; Epenetos et al., 1985; Jackson et al., 1985; Critchley et al., 1986; Shepherd et al., 1987; Jobling et al., 1990 ) but is still not part of routine investigations for ovarian cancer in all specialist centres. Granowska et al. (1993a) , however, demonstrated that 99Tcm-labelled anti-PEM monoclonal antibodies produced a 100% sensitivity with a 73% specificty for ovarian cancer in external scanning. As a label, 99Tcm has the added advantage of a short half-life (6 h), allowing a high activity to be administered, giving a high count rate signal. Numerous monoclonal antibodies have been used for radioimmunodetection, including those against PEM, placental alkaline phosphatase and a number of other epitopes (Granowska et al., 1984; Shepherd et al., 1987) . Studies with flow cytometry have shown that the monoclonal antibody SM3 has a higher specificity for ovarian carcinoma than other antibodies (Van Dam et al., 1991) . This led Jobling et al. (1991) and Granowska et al., 1990 Granowska et al., , 1993a to use SM3-radiolabelled 99Tcm as the first choice for radioimmunoscintigraphy.
The use of PROD in peroperative detection has been explored in colorectal but not in ovarian cancer (Martin et al., 1985; Granowska et al., 1991; Kuhn et al., 1991; Petty et al., 1991; Waddington et al., 1991) . Martin et al. (1985) first demonstrated raised levels of activity in colorectal tumours using iodine-125-labelled polyclonal antibody against carcinoembryonic antigen. Petty et al. (1991) correctly identified the presence of tumour in 8 of 13 histologically confirmed sites using an uptake ratio of 2:1 for the iodine-125-labelled monoclonal antibody 17-lA. Granowska et al. (1993b) demonstrated that, using an uptake ratio of greater than 1.5:1 with 99TcmNlabelled monoclonal antibody 1A3 correctly identified 17 of 19 histologically colorectal tumour sites.
In conclusion, the present study demonstrates that there is strong binding of antibody SM3 in deposits of ovarian carcinoma. The gamma detection probe can be used in vivo or after resection to measure the uptake of radiotracer quickly and efficiently. With frozen section, by contrast, there is an inevitable interval between resection and a histopathological diagnosis, prolonging the time of anaesthesia. In addition, at frozen section, the diagnosis of borderline and malignant tumours affected by prior radiotherapy or infection can be difficult. Histological examination should provide a definitive diagnosis, but if the result is ambiguous the results of monoclonal antibody uptake in vivo or in vitro may help considerably. In addition, since the test has a 65% sensitivity with a zero false-positive rate for resected tissues, the surgeon could make a positive decision without a histological diagnosis on 65% of occasions that tissue is excised for frozen section. This could prevent subjecting patients with limited or benign disease to the risks of radical surgery.
